The Conversation (0)
Ceregene Inc announced that the controlled Phase 2b clinical study of its gene therapy product, CERE-120, which is designed to deliver neurturin for Parkinson’s disease, did not show statistically significant efficacy on the primary endpoint however one of the important secondary endpoints did show significant benefit.
Ceregene Inc announced that the controlled Phase 2b clinical study of its gene therapy product, CERE-120, which is designed to deliver neurturin for Parkinson’s disease, did not show statistically significant efficacy on the primary endpoint however one of the important secondary endpoints did show significant benefit.
As quoted in the press release:
The trial also provided further evidence for the safety of CERE-120 and the dosing methods employed. A marked placebo effect was observed in this trial in that both the sham-surgery-control patients and the CERE-120 treated patients showed significant improvement following their surgery.
Click here to read the full Ceregene Inc report.